Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
Insight Lifetech, a Qiming Venture Partners‑backed innovative medical device manufacturer, has listed on the Shanghai...
Company
Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that the National Medical Products...
Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276), one of China’s largest pharmaceutical companies,...
Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
Akeso, Inc. (HKG: 9926) announced that Yidafang (ivonescimab) has been awarded Breakthrough Therapy Designation (BTD)...
Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) announced that China’s National Medical Products Administration...
HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients
HighTide Therapeutics Inc. (HKG: 2511), the China‑based biopharmaceutical company, announced completion of the Phase IIb...
Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics
Knature Biopharmaceutical Co., Ltd., a China‑based biopharma specializing in mitochondrial medicine, has submitted its initial...
XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery
XtalPi Inc. (QuantumPharm, HKG: 2228), the Sino‑US AI‑powered drug discovery platform, has entered a strategic...
J&J Darzalex Faspro Gets NMPA Approval for Transplant-Eligible Myeloma Patients
Johnson & Johnson (J&J, NYSE: JNJ) announced that Darzalex Faspro (daratumumab and hyaluronidase-fihj) has received National...
Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M
Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) announced plans to transfer its 30% equity...
Everest Medicines Files Velsipity for Ulcerative Colitis in China
Everest Medicines (HKG: 1952) announced it has submitted a marketing filing in China for Velsipity...
Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025
Bristol-Myers Squibb (BMS, NYSE: BMY) reported fourth‑quarter 2025 revenue of USD 12.5 billion, up 1% year‑on‑year (YOY), while...
Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting
Merck & Co. (MSD, NYSE: MRK) announced that Keytruda (pembrolizumab) has received its 20th indication approval...
Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
Eli Lilly and Company (NYSE: LLY) reported fourth‑quarter 2025 revenue of USD 19.29 billion, up 43% year‑on‑year (YOY),...
Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
Novartis AG (NYSE: NVS) reported full‑year 2025 net sales of USD 54.5 billion, up 8% year‑on‑year (YOY) at...
Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug...
GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength
GE HealthCare (NASDAQ: GEHC) reported fourth‑quarter 2025 revenue of USD 5.7 billion, up 7.1% year‑on‑year (YOY), bringing full‑year...
MediTrust Mabwell Insurance Ecosystem Partnership
Shanghai MediTrust Health Technology Group Co., Ltd. (a subsidiary of Shanghai Pharmaceuticals) announced a comprehensive...
Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced the initiation of a Phase I clinical...
Pfizer Launches Migraine Management Zone at China Pharmacy
Pfizer Inc. (NYSE: PFE) in collaboration with GuoDa Drugstore Co., Ltd. (part of Sinopharm) this week...